Observational analysis finds impaired insulin secretion in pancreatic cancer patients, indicating a potential biomarker for diabetes development.
Key Points
Patients with pancreatic cancer demonstrated severe hyperglycemia with impaired insulin secretion before surgery, suggesting a critical link to diabetes.
In a cohort of 160 patients, those with pancreatic ductal adenocarcinoma showed greater insulin deficiency compared to counterparts without cancer.
Assessment using oral glucose tolerance tests revealed significant differences in glucometabolic parameters pre- and post-surgery among patients.
These findings support the hypothesis that alterations in the Wnt5a/beta-catenin pathway may drive diabetes risk in pancreatic cancer patients.